与全球学术和非营利组织的合作协议条款及条件：2021-2026

本报告全面分析了製药和生物技术公司与学术和非营利研究机构之间的合作关係。报告专为业务拓展、许可和研发策略专业人士设计，深入剖析了企业如何与大学、研究机构和非营利组织建立合作关係，以加速创新并开发新疗法。

这份经过全面修订和更新的报告分析了自2021年以来签署的数千份学术和非营利机构合作协议，全面概述了生命科学公司如何与研究机构在发现、开发和商业化活动中合作。

每份协议记录均包含可用的财务资讯以及指向详细线上合约记录的连结。对于已公开备案的协议，本报告还提供向监管机构提交的原始合约文件的存取权限，方便用户查阅合作伙伴之间协商的详细条款。

本报告结合了全面的合约资料、财务基准以及实际合约文件的存取权限，为评估学术合作机会、建立研究伙伴关係以及更有效地进行合约谈判提供了宝贵的见解。

主要优势

• 显着缩短研究时间

您无需搜寻多个资料库、新闻稿和监管文件，即可存取包含数千份学术和非营利合作协议的统一资源。

• 学术合作协议结构基准分析

您可以深入了解製药和生技公司如何与大学和非营利组织建立合作关係，包括研究合作、授权协议和开发伙伴关係。

• 财务条款的可靠分析

仔细审查可用的财务数据，包括关键合约金额、预付款、里程碑付款和特许权使用费结构，以对类似合作的财务价值进行基准分析。

• 查阅实际合约文件

在条件允许的情况下，您可以查阅提交给监管机构的实际学术合作协议，并深入了解通常不会公开的合约条款。

• 识别最活跃的学术合作方

您可以了解哪些製药公司、研究机构和非营利组织在合作方面最为活跃。

• 追踪产业合作趋势

依技术领域、治疗领域和研发阶段分析自 2019 年以来的学术合作活动。

目录

摘要整理

第一章：引言

第2章 跟学术机构·非营利团体的契约动向

• 年度合作趋势
• 最活跃的合作伙伴
• 与学术机构和非营利组织的合作：依合约类型划分
• 与学术机构和非营利组织的合作：依治疗领域划分
• 与学术机构和非营利组织的合作：依技术类型划分
• 合约条款分析
  • 合约总金额
  • 预付款
  • 里程碑付款
  • 特许权使用费率

第三章：与主要学术机构和非营利组织的合约

• 与主要学术机构和非营利组织的合约：依金额划分

第四章：最活跃的学术和非营利合作伙伴

• 最活跃的学术和非营利合作伙伴
• 简介最活跃的学术和非营利合作伙伴公司

第五章：与学术机构和非营利组织的合约目录

• 与学术机构和非营利组织的合约目录

第六章：与学术机构和非营利组织的合约：依技术类型划分

附录

• 附录 1 - 学术与非营利合作伙伴关係：依公司（A-Z）划分
• 附录 2 - 学术与非营利合作伙伴关係：依发展阶段划分
• 附录 3 - 学术与非营利合作伙伴关係：依合约类型划分
• 附录 4 - 学术与非营利合作伙伴关係：依治疗领域划分
• 附录 5 - 合约类型定义
• 附录 6 - 更多信息
• 关于 Biopharma Research Ltd
• 当前合作伙伴关係
• 当前合约
• 近期合作伙伴关係报告标题

Benchmark Academic Collaboration Strategies Across the Global Life Sciences Industry

The Global Academic and Non-Profit Partnering Terms and Agreements 2021-2026 report provides a comprehensive analysis of partnerships between pharmaceutical and biotechnology companies and academic or non-profit research institutions. Designed for business development, licensing, and research strategy professionals, the report delivers detailed insight into how companies structure collaborations with universities, research institutes, and non-profit organizations to accelerate innovation and advance new therapies.

Fully revised and updated, the report analyzes thousands of academic and non-profit partnership agreements announced since 2021, providing an extensive view of how life sciences companies collaborate with research institutions across discovery, development, and commercialization activities.

Each deal record includes financial information where available and links to detailed online deal records. Where agreements have been publicly filed, the report also provides access to the underlying contract documents submitted to regulators, allowing users to review the detailed terms negotiated between partners.

By combining comprehensive deal data, financial benchmarking, and access to real contract documents, the report provides valuable intelligence for evaluating academic collaboration opportunities, structuring research partnerships, and negotiating more effective agreements.

Key Benefits

• Save Significant Research Time

Access a consolidated resource covering thousands of academic and non-profit partnering agreements instead of searching multiple databases, press releases, and regulatory filings.

• Benchmark Academic Collaboration Deal Structures

Understand how pharmaceutical and biotechnology companies structure partnerships with universities and non-profit institutions, including research collaborations, licensing arrangements, and development partnerships.

• Analyze Financial Terms with Confidence

Review available financial data-including headline deal values, upfront payments, milestone payments, and royalty structures-to benchmark the financial value of comparable partnerships.

• Access Real Contract Documents

Where available, explore actual academic collaboration agreements filed with regulators, providing insight into contractual provisions that are rarely disclosed publicly.

• Identify the Most Active Academic Dealmakers

Discover which pharmaceutical companies, research institutions, and non-profit organizations are most active in forming academic partnerships.

• Track Industry Collaboration Trends

Analyze academic partnering activity since 2019 across technologies, therapeutic areas, and development stages.

What's Included in the Report

Analysis of academic and non-profit partnering trends since 2021

Overview of academic collaboration structures and financial models

Review of leading academic partnerships by deal value

Profiles of the most active academic and non-profit dealmakers

Detailed analysis of deals organized by company, development stage, technology type, and therapy area

A comprehensive directory of academic partnering agreements

Links to online deal records and contract documents where available

Deals are indexed across multiple categories-including company A-Z, deal value, development stage, technology type, and therapy target-allowing users to quickly identify comparable transactions.

Due Diligence Insights from Real Agreements

By reviewing actual academic collaboration contracts, the report enables users to evaluate key partnership provisions such as:

• Rights granted or licensed under the collaboration
• Financial payment structures and milestone triggers
• Intellectual property ownership and licensing scope
• Research, development, and commercialization responsibilities
• Exclusivity provisions and territorial rights
• Contract duration, termination clauses, and governance structures
• Access to real agreements provides insight into the detailed terms negotiated between companies and research institutions-information rarely disclosed in press releases or standard deal databases.
• Why This Report Matters
• Partnerships with universities and non-profit research institutions play a critical role in early-stage innovation across the life sciences industry. These collaborations enable companies to access breakthrough research, share development risk, and accelerate the translation of scientific discoveries into commercial therapies.
• By combining comprehensive deal data, financial benchmarking, and access to real contract documents, this report provides the intelligence needed to evaluate academic partnership opportunities, structure stronger research collaborations, and negotiate more effectively.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Academic and Non-Profit dealmaking

• 2.1. Introduction
• 2.2. Academic and Non-Profit partnering over the years
• 2.3. Most active Academic and Non-Profit dealmakers
• 2.4. Academic and Non-Profit partnering by deal type
• 2.5. Academic and Non-Profit partnering by therapy area
• 2.6. Academic and Non-Profit partnering by technology type
• 2.7. Deal terms for Academic and Non-Profit partnering
  • 2.7.1 Academic and Non-Profit partnering headline values
  • 2.7.2 Academic and Non-Profit deal upfront payments
  • 2.7.3 Academic and Non-Profit deal milestone payments
  • 2.7.4 Academic and Non-Profit royalty rates

Chapter 3 - Leading Academic and Non-Profit deals

• 3.1. Introduction
• 3.2. Top Academic and Non-Profit deals by value

Chapter 4 - Most active Academic and Non-Profit dealmakers

• 4.1. Introduction
• 4.2. Most active Academic and Non-Profit dealmakers
• 4.3. Most active Academic and Non-Profit partnering company profiles

Chapter 5 - Academic and Non-Profit contracts dealmaking directory

• 5.1. Introduction
• 5.2. Academic and Non-Profit contracts dealmaking directory

Chapter 6 - Academic and Non-Profit dealmaking by technology type

Appendices

• Appendix 1 - Academic and Non-Profit deals by company A-Z
• Appendix 2 - Academic and Non-Profit deals by stage of development
• Appendix 3 - Academic and Non-Profit deals by deal type
• Appendix 4 - Academic and Non-Profit deals by therapy area
• Appendix 5 - Deal type definitions
• Appendix 6 - Further reading
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Academic and Non-Profit partnering since 2021
• Figure 2: Active Academic and Non-Profit dealmaking activity since 2021
• Figure 3: Academic and Non-Profit partnering by deal type since 2021
• Figure 4: Academic and Non-Profit partnering by disease type since 2021
• Figure 5: Academic and Non-Profit partnering by technology type since 2021
• Figure 6: Academic and Non-Profit deals with a headline value
• Figure 7: Academic and Non-Profit deals with an upfront value
• Figure 8: Academic and Non-Profit deals with a milestone value
• Figure 9: Academic and Non-Profit deals with a royalty rate value
• Figure 10: Top Academic and Non-Profit deals by value since 2021
• Figure 11: Most active Academic and Non-Profit dealmakers since 2021